Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Potent 5-HT2A agonist (1) ·
'"`UNIQ--vote-0000083E-QINU`"' CYP2C9 substrate; no clinically active metabolites. The IDNT trial established renoprotection in diabetic nephropathy independent of BP lowering, contributing to the ARB class indication in T2DM with proteinuria'"`UNIQ--ref-0000083F-QINU`"'. (1)
Showing below up to 2 results in range #1 to #2.


